|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
32,990,000 |
Market
Cap: |
626.81(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$9.99 - $19 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Co.'s marketed product, Ocaliva® (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition, Co. is developing OCA for additional indications, including nonalcoholic steatohepatitis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fluitt Randy |
Executive V.P |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,271) |
0 |
|
- |
|
Saylor Denise C |
Senior V.P. |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,040) |
0 |
|
- |
|
Saylor Denise C |
Senior V.P. |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(106,971) |
0 |
|
- |
|
Collins John W |
Chief Executive Officer |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(959,568) |
0 |
|
- |
|
Sulpy Michael D |
Executive V.P |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(290,814) |
0 |
|
- |
|
Speight J Daniel Jr |
Director |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(415) |
0 |
|
- |
|
Coe Jonathan R |
V.P and General Counsel |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(464) |
0 |
|
- |
|
Mashburn Farrell S |
Senior Vice President |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(71,920) |
0 |
|
- |
|
Weiss Arthur G |
Director |
|
2004-11-08 |
4 |
S |
$18.88 |
$220,254 |
D/D |
(11,666) |
0 |
|
- |
|
Weiss Arthur G |
Director |
|
2004-11-08 |
4 |
OE |
$12.20 |
$142,325 |
D/D |
11,666 |
0 |
|
- |
|
Schneider John D Jr |
Director |
|
2004-11-08 |
4 |
S |
$18.89 |
$377,800 |
D/D |
(20,000) |
0 |
|
- |
|
Schneider John D Jr |
Director |
|
2004-11-08 |
4 |
OE |
$7.00 |
$187,600 |
D/D |
20,000 |
0 |
|
- |
|
Schneider John D Jr |
Director |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,005) |
0 |
|
- |
|
Sturm Glenn W |
Director |
|
2004-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(275,472) |
0 |
|
- |
|
Hawn Mark |
Director |
|
2004-11-03 |
4 |
S |
$18.84 |
$219,787 |
D/D |
(11,666) |
0 |
|
- |
|
Hawn Mark |
Director |
|
2004-11-03 |
4 |
OE |
$10.80 |
$125,993 |
D/D |
11,666 |
0 |
|
- |
|
Boggs G Lynn |
President & COO |
|
2004-09-13 |
4 |
D |
$18.60 |
$1,859,830 |
D/D |
(100,000) |
0 |
|
- |
|
Sturm Glenn W |
Director |
|
2004-08-20 |
4 |
OE |
$4.40 |
$110,835 |
D/D |
21,667 |
415,472 |
|
- |
|
Sturm Glenn W |
Director |
|
2004-08-18 |
4 |
OE |
$2.16 |
$46,256 |
D/D |
21,415 |
415,472 |
|
- |
|
Mashburn Farrell S |
Senior Vice President |
|
2004-05-21 |
4 |
D |
$13.88 |
$97,160 |
D/D |
(7,000) |
16,704 |
|
- |
|
Mashburn Farrell S |
Senior Vice President |
|
2004-05-18 |
4 |
D |
$14.08 |
$119,680 |
D/D |
(8,500) |
32,204 |
|
- |
|
Mashburn Farrell S |
Senior Vice President |
|
2004-05-17 |
4 |
D |
$14.06 |
$112,480 |
D/D |
(8,000) |
40,704 |
|
- |
|
Mashburn Farrell S |
Senior Vice President |
|
2004-05-13 |
4 |
D |
$14.58 |
$169,291 |
D/D |
(11,608) |
48,704 |
|
- |
|
Saylor Denise C |
Senior V.P. |
|
2004-04-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,000) |
105,073 |
|
- |
|
Collins John W |
Chief Executive Officer |
|
2004-04-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(300,000) |
959,568 |
|
- |
|
29 Records found
|
|
Page 1 of 2 |
|
|